Mercy announced it has added a new outpatient treatment to fight COVID-19. It's called Regen-COV.
It isn't the newest monoclonal antibody to hit the market, but it has been proven to have good outcomes against the Delta variant.
The "COVID Cocktail" as it is commonly called combines two antibodies to help a patient's immune system fight the infection.
"For patients who may be at risk or have not been vaccinated or if their immune system hasn't responded properly to the vaccine, then this could be given," said Eric Flaming, an antimicrobial stewardship pharmacist at Mercy Hospital.
Flaming said the treatment is authorized under an emergency use authorization (EUA) from the FDA, but has gone through rigorous studies to prove it's effective.
"The evidence shows it decreases the risk of patients progressing to severe disease or death by 70%," said Fleming.
Previously, Mercy had used a different monoclonal antibody cocktail, which is no longer being used due to it not working against some of the variants like the Delta.
"After that point, we started working towards being able to give the Regen-COV, which is still active against the circulating virus," said Flaming.
The treatment works best if given early on, but not everyone is eligible for it.
Patients must be referred by their primary care physician after a positive test. they also must meet one qualifier out of a list of criteria.
"Every different option we can come up with to prevent patients from progressing to severe disease or death is crucial," said Flaming.
If you think you're a candidate for the treatment, Mercy encourages you to reach out to your physician to see if you're eligible and request a referral.